194 related articles for article (PubMed ID: 38203733)
21. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
Tang KT; Lee CH
J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
Park JL; Jeon S; Seo EH; Bae DH; Jeong YM; Kim Y; Bae JS; Kim SK; Jung CK; Kim YS
Thyroid; 2020 Feb; 30(2):192-203. PubMed ID: 31797753
[No Abstract] [Full Text] [Related]
23. Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma: Combined Analysis of Ultrasonography, Fine-Needle Aspiration Biopsy, and BRAF V600E Mutation.
Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
Medicine (Baltimore); 2015 May; 94(21):e760. PubMed ID: 26020381
[TBL] [Abstract][Full Text] [Related]
24. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
Qi W; Shi C; Zhang P; Feng L; Wang J; Chen D
Pathol Res Pract; 2020 Aug; 216(8):153037. PubMed ID: 32703500
[TBL] [Abstract][Full Text] [Related]
25. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.
Brzeziańska E; Pastuszak-Lewandoska D; Wojciechowska K; Migdalska-Sek M; Cyniak-Magierska A; Nawrot E; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):351-9. PubMed ID: 17693984
[TBL] [Abstract][Full Text] [Related]
26. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
28. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
30. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
31. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma.
Pennelli G; Vianello F; Barollo S; Pezzani R; Merante Boschin I; Pelizzo MR; Mantero F; Rugge M; Mian C
Thyroid; 2011 Dec; 21(12):1393-6. PubMed ID: 22136270
[TBL] [Abstract][Full Text] [Related]
32. [Diagnostic Value of American Thyroid Association Guidelines,American College of Radiology Thyroid Imaging Reporting and Data System,and Chinese Thyroid Imaging Reporting and Data System Alone and Combined With BRAF
Lin Y; Luo YK; Li J; Ren XY; Wang HW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):921-928. PubMed ID: 38173102
[TBL] [Abstract][Full Text] [Related]
33. The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management.
Panebianco F; Mazzanti C; Tomei S; Aretini P; Franceschi S; Lessi F; Di Coscio G; Bevilacqua G; Marchetti I
BMC Cancer; 2015 Nov; 15():918. PubMed ID: 26581891
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and management of differentiated thyroid cancer using molecular biology.
Witt RL; Ferris RL; Pribitkin EA; Sherman SI; Steward DL; Nikiforov YE
Laryngoscope; 2013 Apr; 123(4):1059-64. PubMed ID: 23404751
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes.
Pagan M; Kloos RT; Lin CF; Travers KJ; Matsuzaki H; Tom EY; Kim SY; Wong MG; Stewart AC; Huang J; Walsh PS; Monroe RJ; Kennedy GC
BMC Bioinformatics; 2016 Jan; 17 Suppl 1(Suppl 1):6. PubMed ID: 26818556
[TBL] [Abstract][Full Text] [Related]
37. mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation.
Araujo PP; Marcello MA; Tincani AJ; Guilhen AC; Morari EC; Ward LS
Pathol Res Pract; 2012 Aug; 208(8):489-92. PubMed ID: 22770943
[TBL] [Abstract][Full Text] [Related]
38. BRAF
Kaabouch M; Chahdi H; Azouzi N; Oukabli M; Rharrassi I; Boudhas A; Jaddi H; Ababou M; Dakka N; Boichard A; Bakri Y; Dupuy C; Al Bouzidi A; El Hassani RA
Afr Health Sci; 2020 Dec; 20(4):1849-1856. PubMed ID: 34394248
[TBL] [Abstract][Full Text] [Related]
39. DNA Methylation Haplotype Block Markers Efficiently Discriminate Follicular Thyroid Carcinoma from Follicular Adenoma.
Zhang H; Zhang Z; Liu X; Duan H; Xiang T; He Q; Su Z; Wu H; Liang Z
J Clin Endocrinol Metab; 2021 Mar; 106(4):1011-1021. PubMed ID: 33394038
[TBL] [Abstract][Full Text] [Related]
40. Analysis of BRAF(V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies.
Zhang B; Liu S; Zhang Z; Wei J; Qu Y; Wu K; Yang Q; Hou P; Shi B
Diagn Pathol; 2014 Mar; 9():45. PubMed ID: 24588959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
